Vanda Pharmaceuticals (VNDA) Non-Current Assets (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Non-Current Assets data on file, last reported at $140.4 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 37.35% year-over-year to $140.4 million; the trailing twelve-month figure through Mar 2026 stood at $745.5 million (down 13.94% YoY), and the FY2025 full-year result was $141.7 million, down 34.8% from the prior year.
• Non-Current Assets fell to $140.4 million in Q1 2026, from $141.7 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $233.6 million in Q3 2025 to a low of $105.0 million in Q3 2023.
• A 5-year average of $165.7 million and a median of $141.7 million in 2025 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets surged 102.53% in 2024 and tumbled 37.35% in 2026, its largest moves.
• Tracing VNDA's Non-Current Assets over 5 years: stood at $115.0 million in 2022, then soared by 87.46% to $215.5 million in 2023, then gained by 0.84% to $217.3 million in 2024, then sank by 34.8% to $141.7 million in 2025, then retreated by 0.94% to $140.4 million in 2026.
• Business Quant data shows VNDA's Non-Current Assets at $140.4 million in Q1 2026, $141.7 million in Q4 2025, and $233.6 million in Q3 2025.